4Hirakata Y,Matsuda J,Mivazaki Y,et al.Regional variation in the prevalence of extended-spectrum beta-lactamase-producing clinical isolates in the Asia-Pacific region (SENTRY 1998-2002)[J].Diagn Microbiol Infect Dis,2005,52 (4):323-329.
5Kader AA,Kumar A.Prevalence and antimicrobial susceptibility of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a general hospital[J].Ann Saudi Med,2005,25(3):239-242.
6George A, Jacoby M D, Thapar A, etal. The new β-1actamases [J]. NEnglJ Med,2005,352(4):380-391.
7Ozqunes I, Erben N, Kiremitci A, et al. The prevalence of extended spectrum beta lactamase-producing Escherichia coli and Klebsiella pneumoniae in clinical isolates and risk factors[J]. Saudi Med J,2006,27(5) :608-612.
9ShahAA,Hasan F,Armaed S,et al.Characteristics,epidemiology and clinical importance of eme::ging strains of Gram-negative bacilli producing extended spectrumlβ-lactamases.Res Microbiol, 2004,155 : 409.
10Philppe L J,Bonnet R,Michaux c S,et al.Post-antibiotic and post-blactamase inhibitor effects of ceftazidimeplus sulbactam on extended spectrum β-lactasase producing gram negative bacteria.Jouru M of Antimicrobial Chemotherapy,2004,53:616.
